On February 27, 2026, US Department of Health and Human Services Secretary Robert F. Kennedy Jr. announced on Joe Rogan's podcast that approximately 14 of the 19 peptides on the FDA's Category 2 restricted compounding list would be returned to Category 1. The announcement generated enormous media coverage, and a significant amount of inaccurate reporting about what it actually meant.
The February announcement was a policy direction, not a regulatory action. The formal step came on April 15, 2026, when the FDA officially updated its Section 503A bulk drug substances list, removing 12 peptides from Category 2. That action is real and meaningful, but it is not the same as restoring legal compounding access, and understanding the difference matters for anyone making decisions about peptide sourcing or clinical practice.
The regulatory framework, what Categories 1, 2, and 3 actually mean
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can prepare individualised medications for patients with valid prescriptions, but only using bulk drug substances that meet specific criteria. The FDA maintains a running list divided into three categories that govern what licensed compounding pharmacies can legally use.
Category 1, Under Evaluation: The FDA is actively reviewing the evidence. Substances in Category 1 can generally be compounded under the agency's enforcement discretion policy while evaluation proceeds. This is the status that enables legal access through licensed pharmacies.
Category 2, Significant safety concerns: Substances the FDA has determined raise significant safety risks for compounding. Placement here explicitly prohibits licensed compounding pharmacies from using the substance. This is where BPC-157, TB-500, and others were placed in 2023.
Category 3, Under review for nomination: Substances nominated for evaluation but not yet formally categorised.
Removal from Category 2 removes the explicit prohibition designation. It does not place a substance on the 503A authorised bulks list. Compounding pharmacies are not automatically permitted to resume producing removed compounds. For a substance to be legally compoundable, it must either appear on the 503A authorised bulks list or be under active Category 1 evaluation with enforcement discretion in place. As of June 2026, the 12 removed peptides are in a regulatory grey zone, neither explicitly prohibited nor formally authorised.
The backstory, why these peptides were restricted in the first place
In late 2023, the FDA moved 19 widely used peptides to Category 2, citing three primary concerns: immunogenicity (risk of triggering immune reactions), manufacturing impurities from unregulated synthesis facilities, and a lack of robust human clinical trial data. The action was controversial in the functional medicine community because it simultaneously eliminated the supervised compounding pathway without reducing consumer access to grey-market products.
The predictable result was exactly what critics warned: patients who had been receiving physician-supervised BPC-157 or TB-500 through licensed compounding pharmacies, with sterility testing, potency verification, and pharmaceutical-grade manufacturing, switched to unregulated online research chemical vendors. Demand did not decrease. Quality assurance did.
This is the core argument the Kennedy announcement and subsequent FDA actions have implicitly acknowledged: the 2023 restrictions pushed demand underground rather than reducing it, and restoring the supervised compounding pathway would improve safety outcomes rather than undermining them.
The April 15, 2026 action, what the FDA actually did
The FDA's formal April 15 update removed 12 peptides from its Category 2 list. The removal was triggered by withdrawal of the original safety-concern nominations, the mechanism by which Category 2 status is assigned and removed.
The 12 peptides removed from Category 2 as of April 15, 2026:
Several peptides from the original 2023 restriction are expected to remain restricted due to ongoing safety concerns: GHRP-2, GHRP-6, and a small number of others were not included in the removal action.
The July 23–24, 2026 PCAC meeting, the real decision point
The Pharmacy Compounding Advisory Committee meeting at FDA's White Oak Campus in Silver Spring, Maryland on July 23–24 is the next formal gate in this process. The PCAC is an independent scientific advisory committee that evaluates the evidence and provides recommendations to the FDA. Its recommendations are advisory, not binding, but the FDA typically follows them.
July 23 agenda: BPC-157, KPV, TB-500, MOTS-c
July 24 agenda: Emideltide (DSIP), Semax, Epitalon
For each compound, the committee will evaluate historical safety data, adverse event reports, clinical utility, and the evidence base for the nominated uses. Nominators of each substance will make brief supporting presentations. The public docket (FDA-2026-N-2979) is open for written comments, comments submitted by July 9 were formally provided to PCAC members ahead of the meeting.
PCAC outcomes, July 23–24, 2026
The meeting concluded on July 24, 2026. Six of the seven peptides were recommended for the 503A Bulks List. The committee overruled FDA's own career scientists, who had recommended against all seven, in what observers described as a historic outcome. An audible gasp was heard in the meeting room when the first BPC-157 tally was read.
Nothing changed legally on July 24. A PCAC recommendation is advisory, not binding, not a rule change. Compounding pharmacies cannot legally prepare any of these six compounds under 503A today that they could not yesterday. The FDA must now review the votes, the meeting record, and public comments, then decide whether to open formal rulemaking. That rulemaking process typically takes 8–24 months. Realistic availability through licensed compounding pharmacies, if the FDA proceeds, runs into late 2027.
What did change: the political and scientific signal is now strongly in favour of restoration. Six compounds cleared a committee that was explicitly advised by FDA career scientists to reject all seven. That signal is difficult for the FDA to ignore, particularly under the current HHS policy direction.
Why DSIP was rejected
DSIP (emideltide) was the meeting's only rejection, falling 6–7 with one abstention. The committee cited several specific concerns: thin human RCT data even by peptide standards, poor chemical characterisation compared to the other compounds on the docket, existing approved therapies for its nominated uses (opioid withdrawal and chronic insomnia), and a withdrawn nomination the FDA was evaluating at its own discretion rather than from an active nominator. The DSIP rejection does not close the door permanently, compounds can be re-nominated in future PCAC cycles, but it signals the committee needed more human evidence than what was presented.
Why the committee overruled FDA scientists
The FDA's own briefing documents recommended against all seven compounds on grounds of insufficient safety data, lack of chemical standardisation, and thin human clinical evidence. The committee majority disagreed, not on the science, but on the framework. The yes votes largely prioritised harm reduction: the argument that a supervised, quality-verified compounding pathway is safer than the grey market that currently supplies these compounds, regardless of whether efficacy is proven. The dissenting votes warned that a favourable recommendation could be misread by the public as an efficacy endorsement. Both positions are defensible. The committee landed on access over certainty.
What comes next, the rulemaking process
The positive PCAC recommendations for BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon now trigger FDA review. If the FDA accepts the committee's recommendations, it will open formal rulemaking to formally add them to the 503A authorised bulks list. Once on that list, licensed 503A compounding pharmacies could legally prepare these compounds for patients with valid prescriptions, with pharmaceutical-grade manufacturing, sterility testing, and potency verification.
This would represent a meaningful improvement in the quality and safety of access for patients currently sourcing these compounds through grey-market channels. It would not make them FDA-approved drugs, establish validated indications, or create standardised dosing guidelines. The evidence quality questions that motivated the original 2023 restrictions would remain, the regulatory change is about access pathway, not evidence.
The GLP-1 situation is also worth understanding clearly. Semaglutide and tirzepatide were never on the 503A or 503B bulks lists, they were compounded during FDA-declared shortage periods, and that pathway closed when the FDA determined the shortage had ended. The PCAC meeting does not affect GLP-1 compounding status. 503A pharmacies are currently limited to four or fewer prescriptions per month for compounded versions of FDA-approved GLP-1 drugs, under specific clinical justification criteria.
What hasn't changed, the WADA situation
The regulatory shift affects FDA compounding law in the United States. It has no effect on the World Anti-Doping Agency's prohibited list. BPC-157 has been on the WADA prohibited list since 2022. TB-500, growth hormone secretagogues (ipamorelin, CJC-1295, sermorelin), and peptide hormones remain prohibited for competitive athletes regardless of US compounding legality. Any athlete subject to testing should treat these as prohibited regardless of what the PCAC meeting produces.
FDA regulation is one layer of the compliance landscape. State boards of pharmacy maintain independent authority over compounding practices, and several states have adopted positions on peptide compounding that are more restrictive than the federal framework. A positive PCAC recommendation and subsequent FDA rulemaking would establish federal permission, but individual states could maintain stricter positions. Multi-state practices should assess applicable state requirements independently.
What this means practically right now
For patients currently using compounded peptides: the grey zone continues until the PCAC meeting concludes and the FDA acts on its recommendations. The April removal from Category 2 has reduced the explicit prohibition but has not restored a clear legal compounding pathway. Some compounding pharmacies are interpreting the removal more permissively than others, the legal risk is real and varies by facility.
For patients sourcing through research chemical vendors: the regulatory change is essentially irrelevant to this pathway, which was never governed by the 503A framework in the first place. The quality assurance problem, contamination, incorrect dosing, undeclared compounds, remains the primary practical concern regardless of regulatory developments. COA verification from independent laboratories is the non-negotiable minimum standard.
For practitioners: the July 23–24 PCAC meeting outcome will be the clearest signal about whether and when to resume prescribing these compounds through compounding pharmacies. A positive recommendation followed by FDA rulemaking would restore the supervised clinical pathway that the 2023 restriction eliminated.